Non-Cystic Fibrosis Bronchiectasis Treatment Market to Reach USD 3.5 Bn by 2035 at 5.8% CAGR, Driven by rising disease burden ...

A study led by the Research Institute of the McGill University Health Center (The Institute) has identified a rare genetic ...

The George Soros protege has generated legendary returns for decades, so it's hard not to take stock in where Druckenmiller ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the ...

Elexacaftor-tezacaftor-ivacaftor (ETI) may improve bronchial dilatations in adolescents with cystic fibrosis (CF).

AAT is produced by the liver but helps the lungs defend against inflammation and outside irritants such as smoke or other environmental exposures. “COPD prevalence is especially high in the veteran ...

Biotech is on track to deliver this year one of its best years of annual returns since the sector’s heady days of the Covid ...

Insmed Incorporated recently announced that the European Commission approved BRINSUPRI (brensocatib 25 mg tablets) for treating non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years and older ...

Respiratory medicine has witnessed substantial progress with the introduction of advanced lung function tests, particularly ...

A new study reveals that chulha smoke may be harming Indian women's lungs as severely as long-term cigarette smoking. Doctors ...

AN 86-year-old cyclist has taken on a unique challenge to scale the height of Olympus Mons. Whitehaven's Gerard McCarten ...